These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 35900152)
61. IL-25 participates in keratinocyte-driven dermal matrix turnover and is reduced in systemic sclerosis epidermis. Russo B; Borowczyk J; Cacialli P; Moguelet P; Truchetet ME; Modarressi A; Brembilla NC; Bertrand J; Boehncke WH; Chizzolini C Rheumatology (Oxford); 2022 Nov; 61(11):4558-4569. PubMed ID: 35171244 [TBL] [Abstract][Full Text] [Related]
62. Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis. Raschi E; Privitera D; Bodio C; Lonati PA; Borghi MO; Ingegnoli F; Meroni PL; Chighizola CB Arthritis Res Ther; 2020 Nov; 22(1):265. PubMed ID: 33168071 [TBL] [Abstract][Full Text] [Related]
63. Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta. Xu WD; Leroy EC; Smith EA J Rheumatol; 1991 Feb; 18(2):241-6. PubMed ID: 2023218 [TBL] [Abstract][Full Text] [Related]
67. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. Dees C; Tomcik M; Palumbo-Zerr K; Distler A; Beyer C; Lang V; Horn A; Zerr P; Zwerina J; Gelse K; Distler O; Schett G; Distler JH Arthritis Rheum; 2012 Sep; 64(9):3006-15. PubMed ID: 22549363 [TBL] [Abstract][Full Text] [Related]
68. Regulation of connective tissue synthesis in systemic sclerosis. Varga J; Bashey RI Int Rev Immunol; 1995; 12(2-4):187-99. PubMed ID: 7650421 [TBL] [Abstract][Full Text] [Related]
69. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate. Dooley A; Shi-Wen X; Aden N; Tranah T; Desai N; Denton CP; Abraham DJ; Bruckdorfer R Rheumatology (Oxford); 2010 Nov; 49(11):2024-36. PubMed ID: 20627968 [TBL] [Abstract][Full Text] [Related]
70. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Lambrecht S; Smith V; De Wilde K; Coudenys J; Decuman S; Deforce D; De Keyser F; Elewaut D Arthritis Rheumatol; 2014 Feb; 66(2):418-27. PubMed ID: 24504814 [TBL] [Abstract][Full Text] [Related]
71. A profibrotic role for thymic stromal lymphopoietin in systemic sclerosis. Usategui A; Criado G; Izquierdo E; Del Rey MJ; Carreira PE; Ortiz P; Leonard WJ; Pablos JL Ann Rheum Dis; 2013 Dec; 72(12):2018-23. PubMed ID: 23413283 [TBL] [Abstract][Full Text] [Related]
72. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Akamata K; Wei J; Bhattacharyya M; Cheresh P; Bonner MY; Arbiser JL; Raparia K; Gupta MP; Kamp DW; Varga J Oncotarget; 2016 Oct; 7(43):69321-69336. PubMed ID: 27732568 [TBL] [Abstract][Full Text] [Related]
73. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235 [TBL] [Abstract][Full Text] [Related]
74. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. Ludwicka A; Ohba T; Trojanowska M; Yamakage A; Strange C; Smith EA; Leroy EC; Sutherland S; Silver RM J Rheumatol; 1995 Oct; 22(10):1876-83. PubMed ID: 8991985 [TBL] [Abstract][Full Text] [Related]
75. A potential new approach for treating systemic sclerosis: Dedifferentiation of SSc fibroblasts and change in the microenvironment by blocking store-operated Ca2+ entry. Wu CY; Hsu WL; Tsai MH; Chai CY; Yen CJ; Chen CH; Lu JH; Yu HS; Yoshioka T PLoS One; 2019; 14(3):e0213400. PubMed ID: 30870448 [TBL] [Abstract][Full Text] [Related]